# Amarin Corporation plc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Amarin Corporation plc).

## Overview

Amarin Corporation plc is a pharmaceutical company centered on cardiovascular risk reduction therapies, with its business largely built around a single branded product, VASCEPA (icosapent ethyl). VASCEPA is FDA-approved for severe hypertriglyceridemia and, based on the REDUCE-IT outcomes trial, for reducing persistent cardiovascular risk in select high-risk patients as an adjunct to maximally tolerated statin therapy. The company supplies branded VASCEPA to markets where it sells directly and to territories where third-party partners commercialize the product and pay Amarin for supply and/or royalties. Amarin is incorporated in England and Wales, with principal offices in Dublin and operating presence in the U.S. and multiple European countries.

## Products & services

• VASCEPA® (icosapent ethyl) 1g capsules
• VASCEPA® (icosapent ethyl) 0.5g capsules
• Supply of branded VASCEPA to international partners
• Licensing & distribution agreements (upfront/milestones/royalties)
• Cardiovascular outcomes evidence package (REDUCE-IT® label support)

- **U.S. VASCEPA product sales** (70%) — Direct U.S. sales of VASCEPA capsules to wholesalers, pharmacies and mail-order providers.
- **International partner supply (ex-U.S.)** (20%) — Sales of branded VASCEPA supplied to commercial partners for resale in their territories.
- **Licensing and royalty revenue** (10%) — Upfront, milestone and sales-based payments from license/distribution agreements outside the U.S.

- VASCEPA (icosapent ethyl) 1g capsules
- VASCEPA (icosapent ethyl) 0.5g capsules
- Supply of branded VASCEPA to international partners
- Licensing & distribution agreements (upfront/milestones/royalties)
- Cardiovascular outcomes evidence package (REDUCE-IT label support)

## Customers

Amarin’s core customers are pharmaceutical wholesalers and pharmacy channel intermediaries that purchase VASCEPA and resell it for dispensing to patients. In the U.S., the company sells principally to three major wholesalers, supplemented by regional wholesalers, mail-order pharmacy providers, and select retail pharmacy chains. Demand is ultimately driven by prescribers treating high-risk cardiovascular patients, but access and net pricing are heavily influenced by payers and pharmacy benefit managers (PBMs) through formulary coverage and rebates. Outside the U.S., a meaningful portion of revenue comes from commercial partners that buy product from Amarin and handle local promotion and resale, and from licensing/royalty arrangements tied to partner sales performance. Customer concentration is material: three U.S. customers each represented 10%+ of gross product sales in 2025 and 2024.

- **U.S. wholesalers and pharmacy channel intermediaries** (primary) — Purchase VASCEPA in bulk for downstream distribution to pharmacies; key driver of U.S. revenue and receivables concentration.
- **International commercial partners (license/distribution)** (secondary) — Buy supplied product and/or pay royalties to commercialize VASCEPA/VAZKEPA in agreed territories, bearing local selling costs.
- **Retail and mail-order pharmacies (direct/selected)** (secondary) — Acquire product to dispense to patients; supports reach and access in specific channels.
- **Payers and PBMs (access gatekeepers)** (primary) — Do not typically buy product directly but determine coverage and patient out-of-pocket costs, affecting volume and net price via rebates.

- Big U.S. pharmaceutical wholesalers buying VASCEPA for distribution
- Regional wholesalers and mail-order pharmacies serving chronic patients
- Retail pharmacy chains purchasing directly in select cases
- International commercial partners reselling VASCEPA in their territories
- Payers/PBMs influence volume via formulary coverage and rebate dynamics
- Cardiologists/primary care prescribers drive patient-level demand

## Geography

Amarin’s revenue base is primarily U.S.-driven, with additional sales in certain European countries and other markets through collaborations with third-party partners. The company maintains a U.S. operating presence (Bridgewater, New Jersey) and a European footprint through subsidiaries in countries including Ireland, Switzerland, Germany, France, the U.K., Italy, Spain, Austria, Belgium, Denmark, Finland, Greece, the Netherlands, Norway, Portugal and Sweden. Outside the U.S., the company’s economics differ by route-to-market: direct sales to wholesalers can carry higher net pricing than partner supply arrangements where partners fund promotion and resale. Geographic expansion and performance depend on country-by-country pricing and reimbursement outcomes, and on partner execution (e.g., the EU Territory licensing arrangement with Recordati). No authoritative percentage revenue-by-region table was provided in the excerpts, so a precise regional split is not disclosed here.

- United States remains the main market for VASCEPA prescriptions and revenue
- Europe presence via multiple subsidiaries supporting Irish operations
- Ex-U.S. sales include Europe and select non-U.S./non-Europe partner territories
- Partner model shifts margin profile vs direct selling due to partner promo costs
- Country pricing/reimbursement approvals are key to ex-U.S. uptake
- Corporate structure spans England/Wales incorporation and Dublin principal office

## Strategy

Amarin’s near-term strategy centers on sustaining and defending the U.S. VASCEPA franchise despite generic competition and payer/PBM access volatility, while continuing to serve patient demand through the wholesale and pharmacy channels. In parallel, the company is leaning more heavily on partnerships to expand ex-U.S. commercialization, including supporting partners’ pricing and reimbursement work to unlock access in additional geographies. The company also seeks to grow licensing and royalty streams tied to partner sales, which can diversify revenue away from direct U.S. product sales. Operationally, the strategy implies careful management of supply, inventory and channel dynamics, because shipment timing and wholesaler inventory levels can affect reported revenue versus prescription trends.

- **Stabilize and optimize U.S. commercialization under generic pressure** (short-term) — U.S. product sales are the primary revenue driver and are sensitive to net price and coverage decisions.
- **Scale ex-U.S. commercialization through partners and licensing** (medium-term) — Partner-led launches and reimbursement wins can expand the addressable market without fully replicating a direct sales infrastructure.

- Defend U.S. VASCEPA demand amid generic and omega-3 substitution pressure
- Work to improve/maintain payer and PBM coverage to support volume
- Support partners to expand access, pricing and reimbursement outside the U.S.
- Grow licensing and royalty revenue tied to partner commercialization success
- Optimize supply and channel execution to manage shipment/inventory volatility
- Focus on cardiovascular risk-reduction positioning supported by REDUCE-IT data

## Risks

Amarin is substantially dependent on a single product (VASCEPA/VAZKEPA), making results highly sensitive to competitive, pricing and access changes affecting that franchise. In the U.S., generic icosapent ethyl competition and consumer substitution toward non-prescription omega-3 products can pressure both volume and net selling price, and payer/PBM coverage decisions can abruptly reduce demand. The company also faces customer concentration risk because a small number of wholesalers account for a large share of gross product sales and receivables. Outside the U.S., commercialization and pricing/reimbursement outcomes depend heavily on partners, creating execution and counterparty risk (including reliance on Recordati for the EU Territory). Like other pharma companies, Amarin is exposed to regulatory, pharmacovigilance, supply chain, and intellectual property risks that can affect market access and product economics.

- **Customer concentration with three U.S. wholesalers** [high] — Three customers each accounted for 10%+ of U.S. gross product sales and a large share of receivables, so loss or reduction could materially impact sales and cash collection.
- **Generic competition for icosapent ethyl in the U.S.** [critical] — Court/patent outcomes enabled generic versions with MARINE labeling, contributing to net price and volume pressure for VASCEPA.
- **Dependence on Recordati for EU Territory commercialization of VAZKEPA** [high] — Payments and market penetration in 59 European-focused countries depend on partner execution, pricing approvals and commercialization success.

- Single-product dependence on VASCEPA/VAZKEPA concentrates business risk
- Generic competition in the U.S. pressures price and share
- PBM/payer coverage losses can reduce volume and worsen net price
- Customer concentration among a few wholesalers raises receivables risk
- Partner execution risk outside the U.S., including EU commercialization
- Pricing and reimbursement approvals may be delayed or unfavorable ex-U.S.
- IP/patent setbacks can accelerate generic entry and erosion
- Supply and inventory management issues can disrupt availability and revenue

## Accounting

Amarin’s revenue recognition is sensitive to channel mechanics: U.S. VASCEPA revenue is recognized upon delivery to distributors/customers, so shipment timing and wholesaler inventory movements can create period-to-period differences versus prescription trends reported by third parties. Net product revenue is reported after significant variable consideration, including allowances, discounts, incentives, rebates, chargebacks and returns; changes in estimates for these items can materially affect reported revenue and gross-to-net. For licensing arrangements, revenue is recognized as performance obligations are satisfied, while sales-based royalties are recognized as earned based on partner sales, requiring judgment about timing and measurement. The company’s income tax accounting involves significant judgment under ASC 740, including valuation allowances when deferred tax assets are not considered more-likely-than-not realizable due to ongoing losses. Going-concern assessment under ASC 205-40 is also a key analytical area given the company’s history of operating losses and reliance on cash and investments to fund operations.

- **Revenue recognition and gross-to-net reserves (product sales)** — Affects net product revenue, receivables, and period comparability
- **Channel inventory and shipment timing vs prescription data** — Affects quarterly revenue trends and working capital interpretation
- **Licensing and royalty revenue recognition** — Affects timing of non-product revenue and earnings volatility
- **Income taxes and valuation allowance (ASC 740)** — Affects effective tax rate, deferred tax balances, and equity

- U.S. revenue recognized on delivery; shipment timing affects quarterly revenue
- Gross-to-net estimates (rebates, chargebacks, returns) drive net revenue
- Co-pay mitigation rebates reduce net product revenue in the U.S.
- Partner sales recognized when partner obtains control of product ex-U.S.
- Licensing revenue depends on performance obligations and milestone terms
- Sales-based royalties recognized as earned based on partner sales
- ASC 740 valuation allowance judgments affect tax expense and DTAs
- ASC 205-40 going-concern assessment depends on cash runway assumptions

---

*Last updated: 2026-09-24T11:22:00.037061+00:00*